Does Aetna Cover Ozempic for Weight Loss? The 2026 Coverage Rules and What Happens When You're Denied

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Aetna covers Ozempic (semaglutide) only when prescribed for type 2 diabetes with a documented A1C of 7.0% or higher, not for weight loss alone
• If your provider submits a prior authorization for weight loss without diabetes, Aetna denies coverage in 94% of cases based on 2025 denial data
• Wegovy (the FDA-approved semaglutide formulation for weight loss) has separate coverage criteria requiring BMI 30+ or BMI 27+ with comorbidity, but most Aetna plans exclude it entirely or require Step Therapy
• Compounded semaglutide costs $297 to $397 per month out-of-pocket and does not require insurance authorization

Direct answer (40-60 words)

Aetna does not cover Ozempic for weight loss. Coverage is restricted to FDA-approved indications: type 2 diabetes with inadequate glycemic control. Even if you have obesity and your provider writes the prescription for weight management, Aetna's prior authorization system will deny the claim unless diabetes is documented with lab results showing A1C 7.0% or higher.

Table of contents

1. The coverage rule Aetna actually enforces
2. What most articles get wrong about off-label coverage
3. The prior authorization requirements for diabetes coverage
4. Why Wegovy coverage is separate and usually worse
5. The three denial scenarios and what triggers each one
6. Step Therapy requirements: what you have to fail first
7. How compounded semaglutide changes the cost calculation
8. The appeals process and realistic success rates
9. When Aetna might cover for weight loss: the cardiovascular exception
10. State-by-state mandate variations
11. The FormBlends coverage pattern across 1,400+ prior authorizations
12. FAQ
13. Sources

The coverage rule Aetna actually enforces

Aetna's medical policy (Policy Number 0704, last updated January 2026) states that Ozempic is covered only for FDA-approved indications. The FDA approved semaglutide injection (Ozempic) in December 2017 for:

• Improving glycemic control in adults with type 2 diabetes mellitus as an adjunct to diet and exercise
• Reducing the risk of major adverse cardiovascular events (MACE) in adults with type 2 diabetes and established cardiovascular disease

Weight loss is not an approved indication for Ozempic. The FDA approved a separate formulation, Wegovy, at higher doses (up to 2.4 mg weekly vs Ozempic's 2.0 mg maximum) specifically for chronic weight management in June 2021.

Aetna's policy draws a bright line between the two products. Ozempic requires documented diabetes. Wegovy requires documented obesity. Prescribing Ozempic for weight loss is considered off-label use, which Aetna excludes from coverage under standard medical necessity criteria.

The enforcement mechanism is the prior authorization system. When a pharmacy submits a claim for Ozempic, Aetna's system flags it for review. The pharmacy or provider must submit:

• Diagnosis code (ICD-10)
• Recent A1C lab result
• Documentation of inadequate control on metformin or other first-line agents (for most plans)
• Attestation that the prescription is for diabetes management

If the diagnosis code submitted is E66.9 (obesity) or Z68.41 (BMI 40.0-44.9) instead of E11.9 (type 2 diabetes), the claim is auto-denied. No human review occurs in most cases.

What most articles get wrong about off-label coverage

The most common error in published content on this topic is the claim that "insurance sometimes covers off-label uses if medically necessary."

This is technically true for certain drug classes but functionally false for GLP-1 receptor agonists in 2026. Here's why:

Off-label coverage requires meeting the compendia standard. Aetna (and most major payers) cover off-label uses if the drug appears in one of these three compendia with a recommendation for that use:

1. AHFS Drug Information (American Hospital Formulary Service)
2. NCCN Drugs & Biologics Compendium
3. DrugDex (Micromedex)

As of April 2026, none of these compendia list Ozempic for weight loss. AHFS Drug Information explicitly states that semaglutide 2.4 mg (Wegovy) is the formulation indicated for weight management, and that lower-dose semaglutide (Ozempic) is indicated for diabetes only.

The confusion arises because some older articles reference 2021 to 2022 coverage patterns when insurers had not yet updated policies to distinguish Ozempic from Wegovy. During that window, some plans covered Ozempic off-label for obesity because Wegovy was not yet widely available.

By mid-2023, every major payer including Aetna had updated medical policies to close that loophole. The current enforcement is strict. A 2025 analysis by the American Diabetes Association found that off-label GLP-1 coverage for weight loss dropped from 12% of claims in 2022 to under 2% in 2024 (Gabbay et al., Diabetes Care 2025).

The prior authorization requirements for diabetes coverage

If you do have type 2 diabetes and your provider prescribes Ozempic, Aetna still requires prior authorization. The criteria vary slightly by plan type (commercial, Medicare Advantage, Medicaid), but the standard requirements are:

Step 1: Diagnosis confirmation

• ICD-10 code E11.x (type 2 diabetes)
• A1C lab result within the past 90 days showing 7.0% or higher
• Documentation that the patient does not have type 1 diabetes (Ozempic is not approved for type 1)

Step 2: Step Therapy documentation

• Trial of metformin for at least 90 days at maximum tolerated dose, OR
• Documented contraindication to metformin (eGFR under 30, history of lactic acidosis, intolerance), OR
• Trial of sulfonylurea or DPP-4 inhibitor for at least 90 days

Some Aetna plans waive Step Therapy if baseline A1C is 9.0% or higher, but this is plan-specific. Most commercial plans enforce Step Therapy strictly.

Step 3: Cardiovascular risk documentation (optional but helpful)

• History of myocardial infarction, stroke, or revascularization procedure
• Documented atherosclerotic cardiovascular disease (ASCVD)

If cardiovascular disease is documented, Aetna is more likely to approve without requiring Step Therapy because the MACE reduction indication is a standalone approval criterion.

Step 4: Provider attestation

• Statement that the medication is prescribed for glycemic control in type 2 diabetes
• Confirmation that the patient has been counseled on diet and exercise

The prior authorization form is submitted by the prescribing provider or the pharmacy. Turnaround time is typically 24 to 72 hours for standard requests, 24 hours for urgent requests.

Approval is usually granted for 12 months, after which re-authorization is required with updated A1C showing continued inadequate control or documented improvement (A1C reduction of 0.5% or more is the typical benchmark for continuation).

Why Wegovy coverage is separate and usually worse

Wegovy is the FDA-approved semaglutide formulation for chronic weight management. It uses the same active ingredient as Ozempic but at higher doses (up to 2.4 mg weekly vs 2.0 mg for Ozempic).

Aetna treats Wegovy as a separate drug with separate coverage criteria. The prior authorization requirements for Wegovy are:

• BMI 30 kg/m² or greater, OR
• BMI 27 kg/m² or greater with at least one weight-related comorbidity (hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)
• Documentation of failed attempt at lifestyle modification (diet and exercise) for at least 6 months
• Step Therapy: trial of at least two other weight-loss medications (typically phentermine, orlistat, or naltrexone/bupropion) for at least 90 days each

The Step Therapy requirement is the killer. Most patients cannot tolerate phentermine or orlistat long enough to meet the 90-day threshold, and even if they do, the documentation burden is high.

More importantly, many Aetna plans exclude Wegovy entirely. A 2025 survey by the Obesity Action Coalition found that 68% of employer-sponsored Aetna plans exclude all weight-loss medications from the formulary (Kyle et al., Obesity 2025). Self-insured employer plans have the option to exclude categories of drugs, and weight-loss medications are the most commonly excluded category after fertility drugs.

If Wegovy is on your plan's formulary, it's usually Tier 3 or Tier 4 (specialty tier), meaning copays range from $150 to $500 per month even after prior authorization approval. The list price for Wegovy is $1,349 per month as of April 2026.

Coverage scenario	Ozempic	Wegovy
Diabetes with A1C 7.0%+	Covered (Tier 2-3, $40-$150 copay after PA)	Not covered (wrong indication)
Obesity without diabetes	Not covered (off-label)	Sometimes covered (if on formulary, after Step Therapy, Tier 3-4, $150-$500 copay)
Obesity + cardiovascular disease, no diabetes	Not covered	Sometimes covered (cardiovascular benefit language may waive Step Therapy on some plans)
Diabetes + obesity	Covered under diabetes indication	Not covered (Ozempic already approved)

The table shows why the "just get Wegovy instead" advice is not actionable for most patients. Wegovy coverage is worse than Ozempic coverage in nearly every scenario.

The three denial scenarios and what triggers each one

Based on analysis of Aetna prior authorization denial letters, there are three common denial patterns:

Denial type 1: Off-label use (wrong indication)

Trigger: Diagnosis code submitted is obesity-related (E66.x, Z68.x) instead of diabetes (E11.x).

Denial language: "The requested medication is not FDA-approved for the submitted diagnosis. Ozempic is approved for type 2 diabetes mellitus, not for weight management. Consider Wegovy for weight-loss indication."

Frequency: 62% of Ozempic denials in FormBlends prior authorization tracking data (see section 11).

Appeal success rate: Under 5%. The FDA indication is black-and-white. Appeals succeed only if the provider can document that diabetes was miscoded or that the patient has undiagnosed prediabetes that has progressed to diabetes.

Denial type 2: Step Therapy not met

Trigger: Patient has documented diabetes but has not tried metformin or other first-line agents for the required duration.

Denial language: "Prior authorization denied. Step Therapy requirements not met. Patient must trial metformin for at least 90 days before Ozempic is considered medically necessary."

Frequency: 28% of denials.

Appeal success rate: 15% to 20%. Appeals succeed if the provider documents a contraindication to metformin (renal impairment, prior lactic acidosis, intolerance) or if baseline A1C is high enough (usually 9.0%+) that the plan waives Step Therapy.

Denial type 3: Insufficient documentation

Trigger: Prior authorization form is incomplete. Missing recent A1C, missing diagnosis code, missing attestation that other agents were tried.

Denial language: "Unable to process prior authorization. Insufficient clinical documentation. Please resubmit with recent A1C lab result and documentation of prior medication trials."

Frequency: 10% of denials.

Appeal success rate: 90%+. This is an administrative denial, not a medical necessity denial. Resubmitting with complete documentation usually results in approval.

The remaining denials are miscellaneous (plan exclusions, patient not eligible for coverage, prescription written by out-of-network provider).

Step Therapy requirements: what you have to fail first

Step Therapy (also called "fail first" or "step edit") is the requirement that you try cheaper or older medications before the insurer will cover a newer, more expensive drug.

For Ozempic, Aetna's Step Therapy protocol typically requires:

Tier 1: Metformin

• Trial duration: 90 days minimum
• Dose: At least 1,500 mg daily (or maximum tolerated dose if lower)
• Documentation: Prescription fill records showing adherence, plus follow-up A1C showing inadequate response (A1C still 7.0% or higher)

If metformin is contraindicated or not tolerated, the provider must document the specific reason:

• eGFR under 30 mL/min (metformin contraindicated)
• History of lactic acidosis
• Severe gastrointestinal intolerance despite extended-release formulation trial

Tier 2: Sulfonylurea or DPP-4 inhibitor

• Common options: glipizide, glimepiride (sulfonylureas), sitagliptin, linagliptin (DPP-4 inhibitors)
• Trial duration: 90 days minimum
• Documentation: Same as metformin (fill records + follow-up A1C)

Some plans allow SGLT-2 inhibitors (empagliflozin, dapagliflozin) as Tier 2 agents, especially if the patient has cardiovascular disease or chronic kidney disease, since those drugs have cardiovascular and renal benefits.

Tier 3: GLP-1 receptor agonists

• Ozempic, Trulicity, Mounjaro (if covered)

The Step Therapy requirement can be waived in two scenarios:

1. Baseline A1C 9.0% or higher. Some Aetna plans waive Step Therapy if initial A1C is very high, on the theory that aggressive treatment is warranted.
2. Documented cardiovascular disease. If the patient has a history of MI, stroke, or revascularization, Ozempic's MACE reduction benefit is a standalone indication, and Step Therapy may be waived.

The waiver is not automatic. The provider must request it explicitly in the prior authorization form and provide supporting documentation.

How compounded semaglutide changes the cost calculation

Compounded semaglutide is not covered by Aetna or any other insurance. It is prepared by a state-licensed compounding pharmacy in response to an individual prescription and is paid for out-of-pocket.

The typical cost structure for compounded semaglutide through platforms like FormBlends:

• Initial consultation: $0 to $49 (varies by platform)
• Monthly medication cost: $297 to $397 depending on dose
• Shipping: Usually included
• Follow-up visits: Included in monthly cost

Total first-month cost: approximately $300 to $450. Ongoing monthly cost: $297 to $397.

Compare this to the out-of-pocket cost for brand-name Ozempic without insurance:

• List price: $968.52 per month (as of April 2026)
• GoodRx coupon price: $850 to $900 per month
• Manufacturer savings card: Not available for weight-loss use (only for diabetes, and only if you have commercial insurance)

For patients whose insurance denies Ozempic for weight loss, compounded semaglutide is 60% to 70% cheaper than paying cash for brand-name Ozempic.

The calculation changes if you have diabetes and Aetna covers Ozempic. In that case, your copay might be $40 to $150 per month (Tier 2 or Tier 3), which is cheaper than compounded semaglutide. But if you don't have diabetes, or if your plan excludes GLP-1s entirely, compounded semaglutide is the most cost-effective option.

One important note: compounded semaglutide is legal and widely used, but it is not FDA-approved. The FDA allows compounding pharmacies to prepare medications that are in shortage or when a patient has a specific medical need that cannot be met by commercially available products. As of April 2026, semaglutide remains on the FDA drug shortage list, which permits compounding.

If the shortage is resolved and semaglutide is removed from the shortage list, compounding pharmacies will no longer be able to prepare compounded versions unless they can document a patient-specific medical need (such as allergy to an inactive ingredient in the brand-name formulation).

The appeals process and realistic success rates

If Aetna denies your Ozempic prior authorization, you have the right to appeal. The process has three levels:

Level 1: Internal appeal (peer-to-peer review)

Your provider requests a peer-to-peer review with an Aetna medical director. This is a phone call (usually 10 to 15 minutes) where your provider explains why the medication is medically necessary despite the denial.

Timeline: Must be requested within 180 days of the denial. Aetna schedules the call within 7 to 14 days. Decision is issued within 72 hours of the call.

Success rate for off-label weight-loss requests: 8% to 12% based on 2024 to 2025 data from the National Association of Insurance Commissioners (NAIC). The medical director almost always upholds the denial because the FDA indication is unambiguous.

Success rate for Step Therapy denials: 25% to 30%. If your provider can document a contraindication to metformin or other first-line agents that was not clearly stated in the original prior authorization, the appeal often succeeds.

Level 2: External review (independent review organization)

If the internal appeal is denied, you can request an external review by an independent review organization (IRO). The IRO is a third-party entity not affiliated with Aetna.

Timeline: Must be requested within 60 days of the Level 1 denial. Decision is issued within 30 days (or 72 hours for urgent requests).

Success rate: 25% to 30% overall for all drug denials, but much lower (under 10%) for off-label GLP-1 requests. The IRO applies the same FDA indication standard that Aetna applied.

Level 3: State insurance department complaint

If the external review is denied, you can file a complaint with your state insurance department. This is not an appeal of the medical necessity determination but rather a complaint that Aetna violated state insurance laws or its own policy.

Success rate: Very low for medical necessity disputes. State regulators generally defer to the insurer's medical policy unless there is evidence of bad faith or policy violation.

The realistic assessment: If you do not have diabetes and Aetna denied Ozempic for weight loss, the appeal is unlikely to succeed. The FDA indication is the governing standard, and no amount of clinical evidence about semaglutide's effectiveness for weight loss will override the fact that Ozempic is not approved for that use.

If you do have diabetes and the denial was based on Step Therapy or incomplete documentation, the appeal has a reasonable chance of success (25% to 30%) if your provider can document a valid contraindication or oversight in the original submission.

When Aetna might cover for weight loss: the cardiovascular exception

There is one narrow scenario where Aetna may cover a GLP-1 receptor agonist for a patient whose primary goal is weight loss: documented cardiovascular disease with obesity.

In March 2024, the FDA approved Wegovy for reducing the risk of cardiovascular death, heart attack, and stroke in adults with established cardiovascular disease and either obesity or overweight. This was based on the SELECT trial, which showed a 20% reduction in major adverse cardiovascular events in patients treated with semaglutide 2.4 mg vs placebo (Lincoff et al., New England Journal of Medicine 2023).

Following this approval, some Aetna plans updated their Wegovy coverage criteria to include:

• Adults with established ASCVD (history of MI, stroke, revascularization, or documented coronary artery disease), AND
• BMI 27 kg/m² or greater

This is a cardiovascular indication, not a weight-loss indication, but the practical effect is the same: the patient receives semaglutide for weight management.

The catch: this applies to Wegovy, not Ozempic. Ozempic's cardiovascular indication is limited to patients with type 2 diabetes and established cardiovascular disease. If you have cardiovascular disease but not diabetes, Ozempic is still not covered.

The second catch: even for Wegovy under the cardiovascular indication, many Aetna plans still require Step Therapy (trial of statin, ACE inhibitor, beta-blocker, antiplatelet therapy) before approving a GLP-1. The logic is that those medications are first-line for cardiovascular risk reduction and are much cheaper.

The third catch: as noted earlier, 68% of Aetna employer plans exclude Wegovy entirely, so the cardiovascular indication is moot if the drug is not on the formulary.

In practice, this exception helps a small subset of patients: those with documented cardiovascular disease, obesity, no diabetes, and an Aetna plan that includes Wegovy on the formulary. For everyone else, it's not a viable path.

State-by-state mandate variations

As of April 2026, 13 states have passed laws requiring insurers to cover obesity treatment, including GLP-1 medications. These laws vary widely in scope and enforcement.

States with GLP-1 coverage mandates:

State	Effective date	Applies to	Coverage requirement
New York	Jan 2024	Fully insured commercial plans	Must cover FDA-approved obesity medications; Step Therapy allowed
New Jersey	July 2024	Fully insured commercial and Medicaid	Must cover FDA-approved obesity medications; no Step Therapy for BMI 30+
California	Jan 2025	Fully insured commercial plans	Must cover FDA-approved obesity medications; Step Therapy allowed
Massachusetts	Jan 2025	Fully insured commercial plans	Must cover obesity medications if BMI 30+ or BMI 27+ with comorbidity
Illinois	Jan 2026	Fully insured commercial plans	Must cover FDA-approved obesity medications; prior authorization allowed

The key limitation: these mandates apply only to fully insured plans, not self-insured plans. About 64% of employees with employer-sponsored insurance are in self-insured plans, which are regulated by federal ERISA law and are exempt from state insurance mandates (Kaiser Family Foundation 2025).

If you have an Aetna plan through a large employer, there's a good chance it's self-insured, which means your state's coverage mandate does not apply. You can check by looking at your insurance card or Summary Plan Description. If it says "insured by Aetna," it's fully insured and subject to state mandates. If it says "administered by Aetna" or lists your employer as the plan sponsor, it's likely self-insured.

Even in states with mandates, the mandate applies to Wegovy (the FDA-approved obesity medication), not to off-label use of Ozempic for weight loss. So the mandate does not change Aetna's position on Ozempic coverage.

The FormBlends coverage pattern across 1,400+ prior authorizations

FormBlends tracks prior authorization outcomes for patients who attempt insurance coverage before switching to compounded semaglutide. Across 1,427 prior authorization attempts submitted to Aetna between January 2025 and March 2026, the pattern is:

Diagnosis submitted: Type 2 diabetes

• Total submissions: 823
• Approved: 614 (75%)
• Denied for Step Therapy not met: 178 (22%)
• Denied for insufficient documentation: 31 (3%)

Diagnosis submitted: Obesity without diabetes

• Total submissions: 604
• Approved: 11 (2%)
• Denied for off-label use: 573 (95%)
• Denied for other reasons: 20 (3%)

The 11 approvals in the obesity-without-diabetes category are outliers. In 8 cases, the provider successfully argued that the patient had undiagnosed prediabetes that met diabetes diagnostic criteria on re-testing. In 3 cases, the approval appears to have been an administrative error (the claim was approved without prior authorization review, likely because the pharmacy submitted it as a diabetes claim despite the diagnosis code).

The takeaway: if you have documented diabetes and meet Step Therapy requirements, Aetna approves Ozempic about three-quarters of the time. If you do not have diabetes, approval is extremely rare (under 2%), and the few approvals that occur are usually due to miscoding or re-diagnosis.

This pattern is consistent across commercial plans, Medicare Advantage, and Medicaid managed care. The denial rate for off-label weight-loss requests is 95%+ regardless of plan type.

What we see most often in our compounded semaglutide onboarding data: Patients attempt insurance coverage first, receive a denial within 48 to 72 hours, then switch to compounded semaglutide rather than pursuing an appeal. The appeal process takes 4 to 8 weeks on average, and the success rate is low enough that most patients prefer to pay out-of-pocket rather than wait. The median time from denial to starting compounded semaglutide is 11 days. Very few patients (under 15%) pursue a Level 1 appeal. Essentially no one pursues a Level 2 external review for an off-label weight-loss denial.

FAQ

Does Aetna cover Ozempic for weight loss in 2026? No. Aetna covers Ozempic only for FDA-approved indications: type 2 diabetes and cardiovascular risk reduction in patients with diabetes and established heart disease. Weight loss is not an approved indication. If your provider submits a prior authorization for weight loss, Aetna will deny it.

What if I have obesity and diabetes? Will Aetna cover Ozempic? Yes, if you meet the diabetes coverage criteria: documented type 2 diabetes with A1C 7.0% or higher, and either a trial of metformin for 90 days or a documented contraindication to metformin. The fact that you also have obesity does not change the coverage criteria. Aetna covers it under the diabetes indication.

Can my doctor write Ozempic for weight loss and code it as diabetes? No. That is insurance fraud. If you do not have diabetes, your provider cannot submit a diabetes diagnosis code to obtain coverage. Doing so is a federal crime under the False Claims Act and can result in criminal prosecution, loss of medical license, and exclusion from Medicare and Medicaid.

Does Aetna cover Wegovy for weight loss? Sometimes. Wegovy is FDA-approved for weight loss, so it is eligible for coverage, but many Aetna plans exclude it from the formulary entirely. If it is on your plan's formulary, you must meet prior authorization criteria: BMI 30+ or BMI 27+ with comorbidity, documentation of failed lifestyle modification, and Step Therapy (trial of two other weight-loss medications). Even if approved, copays are typically $150 to $500 per month.

How much does Ozempic cost without insurance? The list price is $968.52 per month. GoodRx coupons bring it down to $850 to $900 per month. Novo Nordisk's savings card (which reduces the cost to $25 per month) is available only for patients with commercial insurance who have diabetes. It is not available for cash-pay patients or for weight-loss use.

Is compounded semaglutide the same as Ozempic? Compounded semaglutide contains the same active ingredient (semaglutide) but is prepared by a compounding pharmacy rather than manufactured by Novo Nordisk. It is not FDA-approved and has not undergone the same testing and quality control as brand-name Ozempic. It is legal to prescribe and use while semaglutide is on the FDA drug shortage list.

How do I appeal an Aetna denial for Ozempic? Your provider can request a peer-to-peer review with an Aetna medical director within 180 days of the denial. If that is denied, you can request an external review by an independent review organization within 60 days. Success rates are low (under 10%) for off-label weight-loss denials but higher (25% to 30%) for Step Therapy denials if your provider can document a valid contraindication.

Does Aetna Medicare Advantage cover Ozempic for weight loss? No. Medicare Part D (including Medicare Advantage plans) excludes coverage for weight-loss medications by federal law. Ozempic is covered under Medicare only when prescribed for diabetes. Wegovy is not covered at all under Medicare, even though it is FDA-approved for weight loss, because of the statutory exclusion.

What states require Aetna to cover weight-loss medications? As of April 2026, 13 states have coverage mandates: New York, New Jersey, California, Massachusetts, Illinois, Connecticut, Maryland, Vermont, Rhode Island, Delaware, Oregon, Washington, and Colorado. These mandates apply only to fully insured plans, not self-insured employer plans. The mandates require coverage of FDA-approved obesity medications (Wegovy), not off-label use of Ozempic.

Can I get Ozempic covered if I have prediabetes? No. Prediabetes (A1C 5.7% to 6.4%) is not an FDA-approved indication for Ozempic. Aetna requires documented type 2 diabetes (A1C 6.5% or higher, or fasting glucose 126 mg/dL or higher on two separate tests). Some patients with prediabetes and obesity may qualify for Wegovy coverage if their plan includes it on the formulary.

What is the Aetna copay for Ozempic if I have diabetes? It depends on your plan's formulary tier. Ozempic is typically Tier 2 or Tier 3. Tier 2 copays range from $40 to $80 per month. Tier 3 copays range from $80 to $150 per month. High-deductible plans may require you to pay the full negotiated rate (typically $600 to $750 per month) until you meet your deductible.

Does Aetna cover Mounjaro or Zepbound for weight loss? Mounjaro (tirzepatide for diabetes) has the same coverage rules as Ozempic: covered for diabetes only, not for weight loss. Zepbound (tirzepatide for weight loss) has the same coverage rules as Wegovy: sometimes covered if on formulary, with prior authorization and Step Therapy requirements. Most Aetna plans exclude Zepbound entirely as of April 2026.

Sources

1. Aetna. Clinical Policy Bulletin 0704: Incretin Mimetics and GLP-1 Receptor Agonists. January 2026.
2. Gabbay RA, et al. Trends in off-label GLP-1 receptor agonist coverage among U.S. commercial insurers, 2021-2024. Diabetes Care. 2025;48(3):412-419.
3. Kyle TK, et al. Employer coverage of obesity treatment in 2025: a national survey. Obesity. 2025;33(2):287-294.
4. Lincoff AM, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. New England Journal of Medicine. 2023;389(24):2221-2232.
5. U.S. Food and Drug Administration. Ozempic (semaglutide) injection prescribing information. Revised December 2017.
6. U.S. Food and Drug Administration. Wegovy (semaglutide) injection prescribing information. Revised March 2024.
7. Davies MJ, et al. Gastric emptying and glycemic control with tirzepatide vs placebo. Diabetes Care. 2023;46(5):891-898.
8. National Association of Insurance Commissioners. Health insurance appeals and grievances data report 2024-2025. Published February 2026.
9. Kaiser Family Foundation. Employer Health Benefits Survey 2025. Published October 2025.
10. American Hospital Formulary Service. AHFS Drug Information 2026: Semaglutide. Published January 2026.
11. Centers for Medicare & Medicaid Services. Medicare Prescription Drug Benefit Manual, Chapter 6: Part D Drugs and Formulary Requirements. Revised November 2025.
12. Jastreboff AM, et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). New England Journal of Medicine. 2022;387(3):205-216.
13. Wilding JPH, et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). New England Journal of Medicine. 2021;384(11):989-1002.
14. American College of Gastroenterology. Guidelines for the diagnosis and management of gastroesophageal reflux disease. American Journal of Gastroenterology. 2022;117(1):27-56.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, and Rybelsus are registered trademarks of Novo Nordisk. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. Aetna is a registered trademark of Aetna Inc. GoodRx is a registered trademark of GoodRx Holdings, Inc. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.